[DOI] [PubMed] [Google Scholar] 73.Barisic I., Balenovic D., Klicek R., Radic B., Nikitovic B., Drmic D., Udovicic M., Strinic D., Bardak D., Berkopic L., et al
Targeting postsynaptic glutamate receptor scaffolding proteins PSD-95 and PICK1 for obesity treatment
The treatment improves the skins radiance by removing surface buildup, increasing hydration, and delivering active ingredients like Vitamin C, niacinamide, or brightening peptides directly into the skin
FTR reduces Trx-disulfide
"As we look to build an impactful portfolio of medicines to address patient needs, our data presented at ADA 2025 demonstrates not only how we are already delivering for a wide range of these needs with semaglutide, but that we are continuing to invest in innovation to support people living with serious chronic disease." The presentation of the CagriSema REDEFINE 1 and 2 trials are the first ever Phase 3 data presented on a GLP-1 and amylin receptor agonist combination, offering insights into the potential of this investigational medicine